Sugi Predict

Sugi Predict / Compounds / SCHEMBL15480591

SCHEMBL15480591

SCHEMBL15480591

CN(c1ccc(C(=O)NO)cc1)S(=O)(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.61
▸ HDAC8 Q9BY41 10/20 0.59
▸ HDAC6 Q9UBN7 7/20 0.59
▸ HDAC3 O15379 6/20 0.59
▸ HDAC11 Q96DB2 5/20 0.59
▸ MMP9 P14780 1/20 0.52
▸ MMP13 P45452 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ HTT P42858 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ ALOX12 P18054 1/20 0.50
▸ MCHR1 Q99705 1/20 0.49
▸ HPGD P15428 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ GBA1 P04062 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15482262 0.87 HDAC6 (0.64) HDAC1HDAC8HDAC6LMNAMEN1
SCHEMBL15480590 0.86 MAPT (0.68) HDAC1HDAC6LMNAMEN1MAPT
SCHEMBL15482278 0.86 LMNA (0.57) HDAC1HDAC8HDAC6LMNAMEN1
SCHEMBL15480601 0.86 SIRT2 (0.56) HDAC1HDAC6LMNAMEN1MAPT
SCHEMBL15480604 0.84 MEN1 (0.55) HDAC1HDAC8HDAC6HDAC3HDAC11
SCHEMBL15482232 0.84 MAPT (0.52) HDAC1HDAC8HDAC6LMNAMEN1
SCHEMBL15480600 0.84 GBA1 (0.64) HDAC1HDAC8LMNAMEN1MAPT
SCHEMBL15480598 0.82 HPGD (0.52) HDAC1HDAC8HDAC6LMNAMEN1
SCHEMBL15482244 0.82 HPGD (0.69) MMP9MMP13LMNAMEN1MAPT
SCHEMBL8273575 0.81 ATM (0.60) LMNAMEN1MAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC8 4/4885HDAC6 10/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC8 4/4885HDAC6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.